Docteur FABIENNE MARCAILLOU
✨ Profil synthétique
IA · 06/05/2026Le Docteur Fabienne Marcaillou est un rhumatologue hospitalier à Montpellier, titulaire d'un DIU en douleur. Ses recherches portent sur la douleur musculosquelettique, la réhabilitation et les mécanismes de la douleur. Avec un h-index de 8 et 15 publications, elle a également travaillé sur des essais cliniques.
Expertises présumées
- Douleur musculosquelettique
- Réhabilitation
- Dépression majeure
- Traitement de la douleur
- Toxicité neurologique
- Dépendance aux opioïdes
- Essais cliniques
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🎯 Capacités
- Evaluation et Traitement de la douleur (CAPA)
🎓 Diplômes
- DE Docteur en médecine
- Diplôme de Sexologie
📝 Autres formations
- Evaluation et traitement de la douleur
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
🏆 DU / DIU rhumato reconnus
Activité de recherche & publications
Source : bases de données publiques (OpenAlex, PubMed).
h-index
8
h articles cités ≥ h fois chacun. Un h de 8 = 8 publications avec 8+ citations.
Citations
205
Publications
15
i10-index
8
Thématiques principales
- Treatment of Major Depression ×7
- Musculoskeletal pain and rehabilitation ×5
- Pain Mechanisms and Treatments ×5
- Opioid Use Disorder Treatment ×3
- Anesthesia and Neurotoxicity Research ×3
Affiliations FR : Hôpital Saint Eloi
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Bibliographie
eDOL mHealth App and Web Platform for Self-monitoring and Medical Follow-up of Patients With Chronic Pain: Observational Feasibility Study
2022ArticleJMIR Formative Research
Ketamine in chronic pain: A Delphi survey
2022ArticleEuropean Journal of Pain
Ketamine and Magnesium for Refractory Neuropathic Pain
2020ArticleAnesthesiology
Évolution du bilan éducatif initial du programme d’éducation thérapeutique du patient « Vivradol, la douleur dans la vie » au centre d’évaluation et de traitement de la Douleur de Clermont-Ferrand
2019ArticleDouleurs : Évaluation - Diagnostic - Traitement
<p>Dextromethorphan and memantine after ketamine analgesia: a randomized control trial</p>
2019ArticleDrug Design, Development and Therapy
Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study
2018ArticleDrug Design, Development and Therapy
Effect of ketamine combined with magnesium sulfate in neuropathic pain patients (KETAPAIN): study protocol for a randomized controlled trial
2017ArticleTrials
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Localisation
Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.
Lieu de consultation
CHU MONTPELLIER
191 Avenue DU DOYEN GASTON GIRAUD, 34000 Montpellier
© OpenStreetMap
Tarifs & secteur de conventionnement
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Articles de presse (2)
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
- "Quand un corps silencieux devient bruyant, c’est effroyable" : un projet inédit pour réinsérer les patients au centre anti-douleur de Montpellier - Midi Libre
📰 Midi Libre · 12/08/2025
<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxNNWE3elAtMl9KeTFrMWJLN3p3LWZEZXVnMVNEYU1NNFpVcXRONFgwdGdILW5iQ1ZCbXIxUHNJbXB0SDVOaDk2bzdnR2h1VTB1ZkRYUkV4WDRxaV9GXzJMYTZIc2hkQWxLZU1SaWV4MTBlY0tvUnRRclh0UU9rdWROUkNaVFByVlU5TXl3dFhLbGZnZEltUHBDdHRDSmFrREQ1VUxESXF0aThWTFZHbjVfSWFsaWlpZVNZdE
- Troubles du sommeil, de la mémoire et de la mobilité… Plus de 28 millions de Français souffrent de douleur chronique - Midi Libre
📰 Midi Libre · 20/10/2025
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxNamRndWNFeklPdUZCSXFSZWdVY2puWmwxZ184d3psTEljN2R3Nm13NXItY3ZTWFExcEJnU2JEWWpGcVkyVmVzTU95b1BXVmoyR1lpY2dZZlUzUG1tVXFOYzY1RkxKQ2hhMGh3RVFybVBOZ3JhLVdOQ0o2bmdHZ1dOaWR6WTFMOVgwclBXMFlPQWt1aU04Z0VUU1N3NzNMWUZHeDNsbkhvQmhCQXU2TEdySkJzR0tQRU1PNj
Top publications · les plus citées
- 1Ketamine and Magnesium for Refractory Neuropathic Pain: A Randomized, Double-blind, Crossover Trial
Anesthesiology · 2020
Lire l'abstract Crossref ↓
Background Ketamine is often used for the management of refractory chronic pain. There is, however, a paucity of trials exploring its analgesic effect several weeks after intravenous administration or in association with magnesium. The authors hypothesized that ketamine in neuropathic pain may provide pain relief and cognitive–emotional benefit versus placebo and that a combination with magnesium may have an additive effect for 5 weeks. Methods A randomized, double-blind, crossover, placebo-controlled study (NCT02467517) included 20 patients with neuropathic pain. Each ketamine-naïve patient received one infusion every 35 days in a random order: ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulfate (3g) or placebo/placebo. The primary endpoint was the area under the curve of daily pain intensity for a period of 35 days after infusion. Secondary endpoints included pain (at 7, 15, 21 and 28 days) and health-related, emotional, sleep, and quality of life questionnaires. Results Daily pain intensity was not significantly different between the three groups (n = 20) over 35 days (mean area under the curve = 185 ± 100, 196 ± 92, and 187 ± 90 pain score-days for ketamine, ketamine/magnesium, and placebo, respectively, P = 0.296). The effect size of the main endpoint was −0.2 (95% CI [−0.6 to 0.3]; P = 0.425) for ketamine versus placebo, 0.2 (95% CI [−0.3 to 0.6]; P = 0.445) for placebo versus ketamine/magnesium and -0.4 (95% CI [−0.8 to 0.1]; P = 0.119) for ketamine versus ketamine/magnesium. There were no significant differences in emotional, sleep, and quality of life measures. During placebo, ketamine, and ketamine/magnesium infusions, 10%, 20%, and 35% of patients respectively reported at least one adverse event. Conclusions The results of this trial in neuropathic pain refuted the hypothesis that ketamine provided pain relief at 5 weeks and cognitive–emotional benefit versus placebo and that a combination with magnesium had any additional analgesic effect. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New
- 2Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study
Drug design, development and therapy · 2018
- 3Dextromethorphan and memantine after ketamine analgesia: a randomized control trial
Drug design, development and therapy · 2019
Publications scientifiques (7) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Essai clinique5
▼
Essai clinique5
▼- Ketamine and Magnesium for Refractory Neuropathic Pain: A Randomized, Double-blind, Crossover Trial
Anesthesiology · 2020 · Journal Article
Pickering G, Pereira B, Morel V, Corriger A, et al.
📚 40 cit.🎯 RCR 3.29🩺 Clinique - Dextromethorphan and memantine after ketamine analgesia: a randomized control trial
Drug design, development and therapy · 2019 · Journal Article
Martin E, Sorel M, Morel V, Marcaillou F, et al.
📚 15 cit.🎯 RCR 1.08🩺 Clinique - Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study
Drug design, development and therapy · 2018 · Journal Article
Pickering G, Macian N, Delage N, Picard P, et al.
📚 23 cit.🎯 RCR 1.55🩺 Clinique - Effect of ketamine combined with magnesium sulfate in neuropathic pain patients (KETAPAIN): study protocol for a randomized controlled trial
Trials · 2017 · Journal Article
Delage N, Morel V, Picard P, Marcaillou F, et al.
📚 11 cit.🩺 Clinique - Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients
Contemporary clinical trials · 2014 · Journal Article
Pickering G, Pereira B, Morel V, Tiberghien F, et al.
📚 9 cit.🩺 Clinique
Transversal2
▼
Transversal2
▼- Ketamine in chronic pain: A Delphi survey
European journal of pain (London, England) · 2022 · Journal Article
Voute M, Riant T, Amodéo JM, André G, et al.
📚 13 cit.🎯 RCR 1.92 - eDOL mHealth App and Web Platform for Self-monitoring and Medical Follow-up of Patients With Chronic Pain: Observational Feasibility Study
JMIR formative research · 2022 · Journal Article
Kerckhove N, Delage N, Cambier S, Cantagrel N, et al.
📚 12 cit.🎯 RCR 1.80🔬→🩺 Translationnel
Datasets & protocoles partagés
Effect of ketamine combined with magnesium sulfate in neuropathic pain patients (KETAPAIN): study protocol for a randomized controlled trial
Collection2017FigshareAbstract Background Neuropathic pain is difficult to treat, and the efficacy of recommended drugs remains limited. N-methyl-d-aspartate receptors are implicated, and antagonists are a pharmacological option. Ketamine is
Effect of ketamine combined with magnesium sulfate in neuropathic pain patients (KETAPAIN): study protocol for a randomized controlled trial
Collection2017FigshareAbstract Background Neuropathic pain is difficult to treat, and the efficacy of recommended drugs remains limited. N-methyl-d-aspartate receptors are implicated, and antagonists are a pharmacological option. Ketamine is
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
